Immunocore (NASDAQ:IMCR) Given Outperform Rating at Leerink Partnrs

Immunocore (NASDAQ:IMCR - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Leerink Partnrs in a note issued to investors on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Immunocore's Q1 2024 earnings at ($0.49) EPS, Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.58) EPS and FY2025 earnings at ($2.14) EPS.

Several other research firms have also commented on IMCR. Canaccord Genuity Group raised their price objective on Immunocore from $60.00 to $63.00 and gave the company a "hold" rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. raised their target price on Immunocore from $60.00 to $70.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. HC Wainwright restated a "buy" rating and issued a $90.00 price target on shares of Immunocore in a report on Wednesday, March 6th. SVB Leerink assumed coverage on shares of Immunocore in a research report on Monday. They issued an "outperform" rating and a $74.00 price objective for the company. Finally, Oppenheimer reissued an "outperform" rating and set a $87.00 target price (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $80.92.

Immunocore Trading Up 0.7 %

Shares of NASDAQ IMCR traded up $0.41 during trading on Monday, hitting $59.46. 396,828 shares of the company traded hands, compared to its average volume of 480,633. The firm has a market capitalization of $2.96 billion, a P/E ratio of -51.26 and a beta of 0.92. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $61.68 and a 200-day moving average price of $60.94. Immunocore has a 1 year low of $42.21 and a 1 year high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to analyst estimates of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The business's revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.63) earnings per share. On average, equities analysts predict that Immunocore will post -1.54 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Immunocore during the 3rd quarter valued at about $650,000. TD Asset Management Inc grew its holdings in shares of Immunocore by 109.9% during the third quarter. TD Asset Management Inc now owns 301,920 shares of the company's stock valued at $15,670,000 after purchasing an additional 158,086 shares during the last quarter. Assetmark Inc. raised its position in shares of Immunocore by 54.9% during the 3rd quarter. Assetmark Inc. now owns 11,011 shares of the company's stock worth $571,000 after purchasing an additional 3,902 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Immunocore by 1.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company's stock worth $5,639,000 after purchasing an additional 1,513 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company's stock valued at $43,000 after purchasing an additional 426 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.